MiPlatform Workshop for Histotechnology Society of NSW
Trajan Scientific and Medical (Trajan) led a "Microscopy Photos with Smartphones" session featuring MiPlatform, on 7 November 2015, at a workshop hosted by the Histotechnology Society of NSW, Australia.
40 people participated in the microscopy session led by Alex Anderson, Regional Account Manager - Northern Area, Australia, Trajan Scientific and Medical.
The session included hands-on use of the MiPlatform to take smartphone photos and videos when viewing microscope slides. At the end of the day, one lucky winner received a free MiPlatform - Chandra Parajuli, from Douglass Hanly Moir Pathology.
The MiPlatform is compatible with any smartphone so ask your local Trajan contact for a demonstration and see how it can change the way you study microscope slides.
Photo: MiPlatform is a smartphone adapter which is quick and easy to setup on microscopes.
Photo: MiPlatform maintains microscope-like navigation to fully utilize the advantages of microscope slides.
Photo (Middle): Chandra Parajuli, from Douglass Hanly Moir Pathology zooming in on a microscope slide using his smartphone and MiPlatform.
More information
MiPlatform
Histotechnology Society of NSW
Also in News
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
European patent for Trajan’s hemaPEN
US FDA listing of Trajan’s hemaPEN blood microsampling device
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.